FDA approves first generic Advair Diskus to treat asthma and COPD.- Mylan

The FDA has approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). Mylan obtained approval to market its generic inhaler in three strengths: fluticasone propionate 100 mcg/ salmeterol 50 mcg, fluticasone propionate 250 mcg/ salmeterol 50 mcg and fluticasone propionate 500 mcg/ salmeterol 50 mcg.

�Today�s approval of the first generic drug product for one of the most commonly prescribed asthma and COPD inhalers in the U.S. is part of our longstanding commitment to advance access to lower cost, high quality generic alternatives,� said Janet Woodcock, MD, director of the FDA�s Center for Drug Evaluation and Research. �People living with asthma and COPD know too well the critical importance of having access to the treatment they need to feel better. Today�s approval will bring more competition to the market which will ultimately benefit the patients who rely on this drug.�.